QQQ   416.47 (+0.44%)
AAPL   165.61 (+0.37%)
MSFT   398.69 (-0.11%)
META   479.17 (-0.39%)
GOOGL   156.10 (+1.30%)
AMZN   175.53 (+0.52%)
TSLA   142.27 (-3.25%)
NVDA   783.78 (+2.86%)
AMD   146.97 (+0.23%)
NIO   3.96 (+4.21%)
BABA   70.20 (+1.64%)
T   16.19 (-1.94%)
F   12.86 (+5.93%)
MU   108.05 (+1.20%)
GE   150.26 (+1.49%)
CGC   7.96 (+0.38%)
DIS   112.25 (-0.32%)
AMC   3.31 (+4.75%)
PFE   26.34 (+1.31%)
PYPL   62.86 (+0.88%)
XOM   120.80 (+0.77%)
QQQ   416.47 (+0.44%)
AAPL   165.61 (+0.37%)
MSFT   398.69 (-0.11%)
META   479.17 (-0.39%)
GOOGL   156.10 (+1.30%)
AMZN   175.53 (+0.52%)
TSLA   142.27 (-3.25%)
NVDA   783.78 (+2.86%)
AMD   146.97 (+0.23%)
NIO   3.96 (+4.21%)
BABA   70.20 (+1.64%)
T   16.19 (-1.94%)
F   12.86 (+5.93%)
MU   108.05 (+1.20%)
GE   150.26 (+1.49%)
CGC   7.96 (+0.38%)
DIS   112.25 (-0.32%)
AMC   3.31 (+4.75%)
PFE   26.34 (+1.31%)
PYPL   62.86 (+0.88%)
XOM   120.80 (+0.77%)
QQQ   416.47 (+0.44%)
AAPL   165.61 (+0.37%)
MSFT   398.69 (-0.11%)
META   479.17 (-0.39%)
GOOGL   156.10 (+1.30%)
AMZN   175.53 (+0.52%)
TSLA   142.27 (-3.25%)
NVDA   783.78 (+2.86%)
AMD   146.97 (+0.23%)
NIO   3.96 (+4.21%)
BABA   70.20 (+1.64%)
T   16.19 (-1.94%)
F   12.86 (+5.93%)
MU   108.05 (+1.20%)
GE   150.26 (+1.49%)
CGC   7.96 (+0.38%)
DIS   112.25 (-0.32%)
AMC   3.31 (+4.75%)
PFE   26.34 (+1.31%)
PYPL   62.86 (+0.88%)
XOM   120.80 (+0.77%)
QQQ   416.47 (+0.44%)
AAPL   165.61 (+0.37%)
MSFT   398.69 (-0.11%)
META   479.17 (-0.39%)
GOOGL   156.10 (+1.30%)
AMZN   175.53 (+0.52%)
TSLA   142.27 (-3.25%)
NVDA   783.78 (+2.86%)
AMD   146.97 (+0.23%)
NIO   3.96 (+4.21%)
BABA   70.20 (+1.64%)
T   16.19 (-1.94%)
F   12.86 (+5.93%)
MU   108.05 (+1.20%)
GE   150.26 (+1.49%)
CGC   7.96 (+0.38%)
DIS   112.25 (-0.32%)
AMC   3.31 (+4.75%)
PFE   26.34 (+1.31%)
PYPL   62.86 (+0.88%)
XOM   120.80 (+0.77%)

Ultragenyx Pharmaceutical (RARE) Earnings Date, Estimates & Call Transcripts

$44.18
+1.81 (+4.27%)
(As of 12:45 PM ET)

Earnings Summary

Upcoming
Earnings Date
May. 2Estimated
Actual EPS
(Feb. 15)
-$1.52 Beat By $0.13
Consensus EPS
(Feb. 15)
-$1.65
Skip Charts & View Estimated and Actual Earnings Data

RARE Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

RARE Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Ultragenyx Pharmaceutical Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20242($1.49)($1.44)($1.47) 
Q2 20242($1.40)($1.37)($1.39) 
Q3 20242($1.38)($1.22)($1.30) 
Q4 20242($1.37)($1.19)($1.28) 
FY 20248($5.64)($5.22) ($5.43)

RARE Earnings Date and Information

Ultragenyx Pharmaceutical last released its quarterly earnings results on February 15th, 2024. The biopharmaceutical company reported ($1.52) earnings per share for the quarter, topping analysts' consensus estimates of ($1.65) by $0.13. The firm had revenue of $127.39 million for the quarter, compared to analyst estimates of $119.38 million. Its revenue was up 23.3% compared to the same quarter last year. Ultragenyx Pharmaceutical has generated ($8.33) earnings per share over the last year (($8.33) diluted earnings per share). Earnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($6.36) to ($5.12) per share. Ultragenyx Pharmaceutical has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off prior year's report dates.

Ultragenyx Pharmaceutical Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/2/2024
Estimated)
------- 
2/15/2024Q4 2023($1.65)($1.52)+$0.13($1.52)$119.38 million$127.39 million    
11/2/2023Q3 2023($2.08)($2.23)($0.15)($2.23)$99.38 million$98.05 million
8/3/2023Q2 2023($2.11)($2.25)($0.14)($2.25)$107.10 million$108.30 million    
5/4/2023Q1 2023($1.97)($2.33)($0.36)($2.33)$103.90 million$100.50 million    
2/16/2023Q4 2022($2.03)($2.16)($0.13)($2.16)$105.11 million$103.35 million    
11/2/2022Q3 2022($2.29)($2.43)($0.14)($1.36)$98.76 million$90.70 million
7/28/2022Q2 2022($1.72)($2.26)($0.54)($2.26)$87.33 million$89.34 million    
5/5/2022Q1 2022($1.76)($2.19)($0.43)($2.19)$84.25 million$79.94 million    
2/10/2022Q4 2021($1.32)($1.79)($0.47)($1.79)$83.68 million$83.39 million    
11/2/2021Q3 2021($1.43)($1.08)+$0.35($1.08)$78.16 million$81.65 million    
8/1/2021Q2 2021($1.28)($1.81)($0.53)($1.09)$85.88 million$86.98 million    
5/4/2021Q1 2021($1.25)($2.03)($0.78)($2.03)$77.21 million$99.40 million  

Ultragenyx Pharmaceutical Earnings - Frequently Asked Questions

When is Ultragenyx Pharmaceutical's earnings date?

Ultragenyx Pharmaceutical has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off last year's report dates. Learn more on RARE's earnings history.

Did Ultragenyx Pharmaceutical beat their earnings estimates last quarter?

In the previous quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) reported ($1.52) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.65) by $0.13. Learn more on analysts' earnings estimate vs. RARE's actual earnings.

How can I listen to Ultragenyx Pharmaceutical's earnings conference call?

The conference call for Ultragenyx Pharmaceutical's latest earnings report can be listened to online. Listen to Conference Call

How can I read Ultragenyx Pharmaceutical's conference call transcript?

The conference call transcript for Ultragenyx Pharmaceutical's latest earnings report can be read online. Read Transcript

How much revenue does Ultragenyx Pharmaceutical generate each year?

Ultragenyx Pharmaceutical (NASDAQ:RARE) has a recorded annual revenue of $434.25 million.

How much profit does Ultragenyx Pharmaceutical generate each year?

Ultragenyx Pharmaceutical (NASDAQ:RARE) has a recorded net income of -$606.64 million. RARE has generated -$8.33 earnings per share over the last four quarters.

What is Ultragenyx Pharmaceutical's EPS forecast for next year?

Ultragenyx Pharmaceutical's earnings are expected to grow from ($6.36) per share to ($5.12) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:RARE) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners